Chimpanzee ad vector technology platform for prophylactic and therapeutic genetic vaccine applications by Colloca, Stefano
Engineering Conferences International
ECI Digital Archives
Vaccine Technology IV Proceedings
Spring 5-22-2012
Chimpanzee ad vector technology platform for
prophylactic and therapeutic genetic vaccine
applications
Stefano Colloca
okairos
Follow this and additional works at: http://dc.engconfintl.org/vaccine_iv
Part of the Biomedical Engineering and Bioengineering Commons
This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in
Vaccine Technology IV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.
Recommended Citation
Stefano Colloca, "Chimpanzee ad vector technology platform for prophylactic and therapeutic genetic vaccine applications" in
"Vaccine Technology IV", B. Buckland, University College London, UK; J. Aunins, Janis Biologics, LLC; P. Alves , ITQB/IBET; K.
Jansen, Wyeth Vaccine Research Eds, ECI Symposium Series, (2013). http://dc.engconfintl.org/vaccine_iv/28
Chimpanzee Adenovirus Vectors
Stefano Colloca
Vaccine Technology IV
May 20-25, 2012
Albufeira, Portugal
Contents
• Chimpanzee Adenovirus platform technology
• The ChAd story
• Genetic Adjuvant
• Better cell line
• Immunization modalities
• Combination of different Adeno vectors
• Combination of Adeno and Pox vectors
• Does the order matter?
• Can the same vector be re-administered?
• Can different routes of administration improve immunity/efficacy?
2
Contents
• Chimpanzee Adenovirus platform technology
• The ChAd story
• Genetic Adjuvant
• Better cell line
• Immunization modalities
• Combination of different Adeno vectors
• Combination of Adeno and Pox vectors
• Does the order matter?
• Can the same vector be re-administered?
• Can different routes of administration improve immunity/efficacy?
3
Okairos’ Technology platform
Pillars of Okairos’ platform 
Chimp adeno
vectors
• Potent inducer 
Genetic adjuvant
• Further boosts 
Procell 92 cell 
line
• New highly 
of CD8 T cell 
response
• No pre-existing 
immunity
• Safe and well-
tolerated in ˃ 
500 subjects
CD8 T cell 
response
• Increases rate, 
magnitude, 
breadth and 
duration
• Breaks 
tolerance 
against self-
antigens
productive 
proprietary cell 
line
• Compatible 
with any gene 
insert
• FIM of first 
clinical material 
3Q2012
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Why adeno?
• For some infections, as well as cancer, protection or clearance
can be boosted and they are correlated to a strong T-cell
response
• An efficient way to generate a combined antibody and T-cell
response is through an immune-stimulating vector
Pre-clinical and clinical studies with non replicating human 
adenovirus 5 have shown it to be safe and highly immunogenic
5
• Pre-existing neutralizing antibodies to hAd5 present in
humans reduce frequency and magnitude of response
Adenovirus vectors from rare human serotypes are weak
immunogens in mice and NHP*
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6 * Colloca et al. Science Translational Medicine, in press
Okairos solution: vectors from chimpanzee adenoviruses
• Chimpanzee adenoviruses are closely related to human Ads
• hAd/ChAd cross-neutralization is very limited
• Human cell lines are permissive for ChAds replication
Okairos’ Ad vectors derived from chimpanzees
• Okairos screened samples and isolated virus from over 700 chimpanzees
• All primates were healthy and well cared for in US and EU facilities
• Identified more than 100 strains grouped into 25 distinct serotypes
High
productivity
Okairos’
chimpanzee Ad vectors
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High
potency
Low
pre-existing 
immunity
ChAd vectors are potent immunogens in mice and NHP*
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9 * Colloca et al. Science Translational Medicine, 2012
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Potent Vectors
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ChAd vectors are potent immunogens in mice and NHP*
10 * Colloca et al. Science Translational Medicine, 2012
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ChAd vectors are the most effective Ad vaccine carriers:
single injection of ChAd3 provides full protection against EBOV challenge
ChAd3
100
%
 
p
r
o
t
e
c
t
i
o
n
25
50
75
no vaccine
(N=2)
ChAd3 1010 (N=4)
100
Ad26*
25
50
75
no vaccine
(N=2)
Ad26 1010
Ad26 1011
(N=4)
Ad26 1012
(N=4)
100
Ad35*
25
50
75
no vaccine
(N=2)
Ad35 1011
• Mechanism of protection from Ebola challenge is based on CD8 T cells**
11 * Giesbert TW; J Virol, 2011; collaboration with N.Sullivan & G.Nabel, VRC – NIH - ** Sullivan NJ, Nat Med. 2011 Aug 21;17(9):1128-31
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Single administration of PanAd3 vector expressing RSV F- N/M2-1 and 
challenge experiment with B–RSV in calves
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12 * Collaboration with G. Taylor IAH, UK
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PanAd3-RSV single administration prevents viral replication in lower respiratory 
tract and lung 
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Single administration of PanAd3 vector expressing RSV F- N/M2-1 and 
challenge experiment with B–RSV in calves
13 * Collaboration with G. Taylor IAH, UK
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Control animals shed RSV in nasal secretions by day 2-3, peaking at day 6 post 
challenge
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14 * Collaboration with G. Taylor IAH, UK
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A single administration of PanAd3 blunts viral replication in the upper respiratory tract 
as well
Robust neutralising antibody response generated by RSV vaccine 
candidate (data from RSV vaccine program)
Neutralising titers induced in mice by Okairos RSV vaccine
EC50 = 1/8200
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• Neutralizing antibody titer EC50 = 1/8200 (both A and B RSV types) is 100 fold higher than:
• trough levels present in sera of infants treated with Synagis
• sera from adults and infants protected from hospitalization
Multiple clinical studies have validated the safety and strength of 
ChAd vectors in humans*
HCV
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16 * Barnes et al. Science Translational Medicine, 2012; O’Hara J.Infect. Disease, 2012; Sheehy et al. Molecular Therapy, 2011
Chimp Adeno are insensitive to pre-existing anti-Adeno immunity 
present in in humans (data from HCV vaccine program*)
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MHC-II Invariant chain (li) is a genetic adjuvant
• Fusion of mouse li to Adeno encoded antigen increases presentation on
MHC-I (Holst, J of Immunology 2008)
• Invariant chain fusion increases intra-cellular concentration of antigen – ER
accumulation (P. Holst, unpublished)
 Hypothesis: re-location and intracellular storage of antigen, favourable for
antigen presentation, leads to increased T cell response
19
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MHC-II Invariant chain (li) increases strength of CD4 and CD8 T-
cell response in mice
CD8
CD4
geomean
geomean
• Similar data with 
different Ad vectors 
(ChAd3, ChAd63, 
Ad5) and different 
antigens:
1. Ebola GP
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• 10 outbred mice vaccinated per group
• Test on splenocytes by IFNγ ICS at week 2
• Bar represents geometric mean per group
Vector: ChAd3/NS ChAd3-Ii/NS 
2. Malaria METRAP
3. LCMV GP and NP
4. MHV-68 M2 and M3
5. VSV GP
li improves levels and onset of CD4 and CD8 T-cell response in 
non-human primates
• 4 NHPs immunized per group
• IFNγ ICS data collected at 2 and  4 weeks post vaccination
• Line represents geometric mean
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First in man planned in early 2013
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Procell-92: a novel manufacturing cell line for an unmet 
technological need
Need for a new proprietary cell line with:
• Full history documentation and clean records
• Ability to support production of Ad vectors expressing toxic/interfering transgenes
• Better productivity
Advantages of Procell-92 expressing TetR:
23
• Successful production of genetically stable Ad vectors expressing
toxic/interfering transgenes:
• Ad6-HCV E1E2p7
• ChAd3-HIV GP155
• ChAd63-Malaria CS
• Increased yield of ChAd vectors in comparison to 293 or PER.C6 was
observed for all vectors tested so far
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Heterologous prime/boost with different group C Ad vectors is 
more efficient than homologous prime/boost in NHP
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Heterologous prime/boost with different group C Ad vectors in
NHP and in Humans*
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In humans the heterologous prime/boost with different group C Ad vectors is not
as efficient as in NHP, and ChAd3 is a better primer
• No correlation with anti-vector T cell response
• Some correlation with anti-vector nAb
* Barnes et al. Science Translational Medicine, 2012
ChAd/MVA is the best combination, but the order matters
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The high immunological potency of ChAd/MVA Heterologous prime/boost is 
independent from the ChAd serotype or the antigen (data from Malaria vaccine 
program)
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• Data from different Phase I trials with vectors encoding different Malaria
antigens*
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malaria vaccine clinical trials
28 * O’Hara J.Infect. Disease, 2012; Sheehy et al. Molecular Therapy, 2011
Overview of ChAd/MVA clinical trials completed/ongoing to date
• Over 500 subjects vaccinated
• No safety issue
• 100% response rate
29
• 1000 – 18000 SFC/million PBMC
• Balanced CD4/CD8
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ChAd and MVA vectors can be re-administered in humans
(data from Malaria vaccine program - vectors encoding Malaria METRAP*)
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Intranasal ChAd priming can be efficiently combined with 
intramuscular MVA boosting: the ‘Mixed route’
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‘Mixed-route’ ChAd/MVA regimen is induces highest protection 
from RSV challenge in cotton rats
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PanAd3/MVA RSV vaccine is safe and fully protective against 
heterologous B-RSV challenge in seronegative newborn calves*
            RSV in respiratory tract and lung homogenates
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* Collaboration with G.Taylor, IAH, UK
Phase I study starts 3Q 2012
Intranasal Ad prime does not induce systemic neutralizing 
antibodies to the vector: option for re-administration
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• NHP (N=3) were immunised with 5x10^10 vp PanAd3-RSV by the intranasal (IN)
or intramuscular route (IM)
• nAb measured 4 weeks post immunization
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Administration of the same Ad vector by the ‘Mixed route’:
A new concept for homologous prime/boost
• Priming of Ag-specific 
response
• No induction of systemic 
anti-Adeno antibodies
1° vector 
administration
by intranasal route
2° administration of • Vector is NOT neutralized
37
the same vector by 
intramuscular route
• Efficient boosting of Ag-
specific immunity
Efficient boosting by re-administration of the same ChAd vector 
by the ‘Mixed route’
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‘Mixed route’: a paradigm shift
Heterologous Vectors
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Heterologous Routes
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Procell-91 and Procell-92 Cell line history
• Procell-91 and Procell-92 are proprietary derivative of HEK293, designed to 
optimize vector expression independent of insert
• Obtained 293 cells frozen in 1975 (prior to prion disease onset) from Dr F. 
Graham (p10)
• Cells were expanded under defined conditions to generate a research cell bank 
(p33)
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• Adaptation to suspension growth  
(p48)
• Procell-91 GMP MCB production 
(p59)
Transfection with TetR 
• Adaptation to suspension growth (p103)
• Procell-92 suspension GMP MCB
confidential
Procell-92  allows growth of Ad vectors encoding toxic genes
10^5
Ad6-E1E2p7 productivity
Ad6 vector encoding 3 HCV genes: 1. E1 (transmembrane domain)
2. E2 (transmembrane domain)
3. p7 (highly toxic ion channel protein)
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Increased productivity of ChAd3NSmut in Procell-92
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Ad5 is best-in-class vector for CD8 T cell induction in humans
Ease of
manufacturing
Integration
Pre-existing
Immunity
Clinical
Safety
Immunogenicity
in humans
Human Ad5
Lenti
Alphavirus
excellent
problematic
problematic
none
none
yes
high
none
none
excellent
excellent
untested
very high (>CD8)
high (>CD4)
untested
ALVAC
MVA
DNA
adequate
adequate
excellent
none
none
none
none
none
none
good
good
excellent
low
low
low
• Pre-existing neutralizing antibodies present in humans reduce immunogenicity
(hAd5)
• Human adeno vectors based on rare serotypes are less immunogenic (hAd24,
hAd26, hAd35)
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The ChAd/MVA HCV candidate vaccine induced T cell response is 
well above the ‘protective threshold’
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ChAd3 induced response
ChAd3 prime / MVA boost 
induced response
Protective T cell response*
* Spada et al, 2004, Gut; Folgori et al, 2006, Gut
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The ChAd/MVA regimen induces high levels of  memory response in 
humans  (data from HCV vaccine program*)
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• FDA approved Phase II efficacy study in high risk individuals currently ongoing
in US (collaboration with NIH, J. Hopkins & UCSF)
• First and only prophylactic HCV vaccine in Phase II
• Mechanism based only on T cells
* Collaboration with P.Klenerman & E.Barnes, U.Oxford
Heterologous prime/boost with different ChAd serotypes 
improves T-cell response and allows re-administration
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 Our data suggest that injection of a different vector after priming (another Adeno or MVA)
improves efficacy of re-administration by establishing a larger pool of antigen-specific
memory T cells
ChAd/MVA induces a cross reactive T-cell response across 
divergent HCV genotypes (data from HCV vaccine program*)
1b
1a
HCV genotype used
in ELISPOT assay
Prime vector (dose): ChAd3 (2.5x1010)
Boost vector (dose): MVA (2x108)
Antigen in vectors: genotype 1b
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* Collaboration with P.Klenerman & E.Barnes, U.Oxford
Intranasal (IN) ChAd administration induces both T- and B-cell 
responses in mice and NHP
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Vaccination and challenge experiment in calves: Animals and 
Challenge virus*
Animals:
• 4 -6 weeks old calves
• partially colostrum deprived (fed with colostrum only at birth to avoid
intestinal infections)
• Absence of B-RSV neutralizing antibodies tested by plaque reduction assay
Challenge:
52 confidential
• Highly virulent BRSV isolate 3761 Snook strain
• Isolated from a nasal swab of a calf with distress respiratory syndrome in
2003. The virus was amplified by 3 passages in newborn calves to generate
the BRSV-3761 inoculum
• Animals are infected by Intranasal and intratracheal inoculation of 1 x 104
pfu
• All animals exhibit viral replication in the lung and in the nose and develop
pulmonary disease
* Collaboration with G. Taylor IAH, UK
Malaria – ChAd63/MVA METRAP shows equivalent 
immunogenicity in adults, children and infants
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• First evidence of Adeno immunogenicity in infants
ChAd63/MVA HIV-cons induces the highest T cell immunity 
to date (data from HIV vaccine program)
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• Data from Phase I trial with vectors encoding the HIV-cons antigen*
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54 * Collaboration with T.Hanke, U. Oxford
Heterologous prime/boost with different ChAd serotypes 
improves T-cell response and allows re-administration
IFNγ ELISpot PanAd3gag PanAd1gag PanAd3gag
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 Our data suggest that injection of a different vector after priming (another Adeno or MVA)
improves efficacy of re-administration by establishing a larger pool of antigen-specific
memory T cells
Heterologous prime/boost with different ChAd serotypes 
improves T-cell response and allows re-administration
IFNγ ELISpot on gag antigen Anti-vector T and B cell immunity
at the time of PanAd3 re-administration
T cell response to Ad5 Hexon
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 These data suggest that injection of a different vector after priming (another Adeno or MVA) improves
efficacy of re-administration by establishing a larger pool of antigen-specific memory T cells
ChAd3 induces poly-functional T-cells in humans
(data from HCV vaccine program)
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• ICS and Pentamer staining from a representative volunteer 4 weeks post ChAd3 prime*
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57 * Barnes et al. Science Translational Medicine, 2012
The Okairos RSV vaccine multi-antigen
Vaccine encoded
Antigens
Why F, N and M2-1?
• F is a known protective antigen (The Impact-RSV study group 1998 Pediatrics 102:531)
2A self-cleavage flexible linker
F protein Nucleoprotein Matrix 2-1 protein
524aa∆TM
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• It is highly conserved between strains from the A and B subgroups
• Contains human T cell epitopes (Cherrie AH 1992 J Virol 66:2102)
• Soluble F protein induces higher neutralizing titers than membrane-bound form (Cseke G 2007 J Virol 81:
698; Kohlmann R 2009 J Virol 83:12601)
• N and M2-1 are highly conserved between RSV strains and are known to be a source of many T-cell
epitopes (Anderson R 2010 Future Microbiol 5:585)
• Genetic vaccines encoding either F or N or M2-1 each confer some degree of protection in animal models
(reviewed in Graham B 2011 Immunol Reviews 239: 149; Boxus M 2007J Virol 81:6879)
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